30
Participants
Start Date
October 29, 2018
Primary Completion Date
June 26, 2023
Study Completion Date
December 1, 2023
IVIG
"If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each."
Albumin
This will be the matching placebo used in the study.
UT Southwestern Medical Center, Dallas
Collaborators (1)
Grifols Biologicals, LLC
INDUSTRY
Dysautonomia International
OTHER
University of Texas Southwestern Medical Center
OTHER